Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Eliem Therapeutics (ELYM – Research Report) on June 3 and set a price target of $5.00. The company’s shares closed yesterday at $2.96.
Matteis covers the Healthcare sector, focusing on stocks such as Denali Therapeutics, Xenon, and Athira Pharma. According to TipRanks, Matteis has an average return of 8.8% and a 48.74% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eliem Therapeutics with a $5.00 average price target.
See the top stocks recommended by analysts >>
Based on Eliem Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $22.29 million. In comparison, last year the company had a GAAP net loss of $13.6 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
Read More on ELYM:
